HR 5925 RFS 
‘‘(B) revise such model State drug laws 
and draft supplementary model State laws to 
take into consideration changes in illicit drug 
use issues in the State involved. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $1.25 million for each of fiscal years 
2019 through 2023. 
‘‘(e) DRUG COURT TRAINING AND TECHNICAL AS-
SISTANCE PROGRAM.— 
‘‘(1) GRANTS AUTHORIZED.—The Director may 
make a grant to a nonprofit organization for the 
purpose of providing training and technical assist-
ance to drug courts. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $2 million for each of fiscal years 
2019 through 2023. 
‘‘(f) INTERNATIONAL COORDINATION.—The Director 
may facilitate international drug control coordination ef-
forts. 
‘‘(g) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI-
NATOR.—The Director shall designate or appoint a United 
States State, Local, and Tribal Affairs Coordinator to per-
form the duties of the Office outlined in this section and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00085
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
section 1005 and such other duties as may be determined 
by the Director with respect to coordination of drug con-
trol efforts between agencies and State, local, and Tribal 
governments. The Director shall determine whether the 
coordinator position is a noncareer appointee in the Senior 
Executive Service or a career appointee at the GS–15 level 
(or equivalent) or above. 
‘‘§ 1011. Interdiction 
‘‘(a) UNITED
STATES
INTERDICTION
COORDI-
NATOR.— 
‘‘(1) IN
GENERAL.—The Director shall des-
ignate or appoint a noncareer appointee in the Sen-
ior Executive Service or a career appointee at the 
GS–15 level (or equivalent) or above as the United 
States Interdiction Coordinator to perform the du-
ties of that position described in paragraph (2) and 
such other duties as may be determined by the Di-
rector with respect to coordination of efforts to 
interdict illicit drugs from entering the United 
States. 
‘‘(2) RESPONSIBILITIES.—The United States 
Interdiction Coordinator shall be responsible to the 
Director for— 
‘‘(A) coordinating the interdiction activities 
of the National Drug Control Program Agen-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00086
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
cies to ensure consistency with the National 
Drug Control Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before September 1 of each 
year and in accordance with paragraph (4), a 
National Interdiction Command and Control 
Plan to ensure the coordination and consistency 
described in subparagraph (A); 
‘‘(C) assessing the sufficiency of assets 
committed to illicit drug interdiction by the rel-
evant National Drug Control Program Agen-
cies; and 
‘‘(D) advising the Director on the efforts 
of each National Drug Control Program Agency 
to implement the National Interdiction Com-
mand and Control Plan. 
‘‘(3) STAFF.—The Director shall assign such 
permanent staff of the Office as he considers appro-
priate to assist the United States Interdiction Coor-
dinator to carry out the responsibilities described in 
paragraph (2), and may request that appropriate 
National Drug Control Program Agencies detail or 
assign staff to assist in carrying out such activities. 
‘‘(4) NATIONAL INTERDICTION COMMAND AND 
CONTROL PLAN.— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00087
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(A) PURPOSES.—The National Interdic-
tion Command and Control Plan— 
‘‘(i) shall set forth the Government’s 
strategy for drug interdiction; 
‘‘(ii) shall state the specific roles and 
responsibilities of the relevant National 
Drug Control Program Agencies for imple-
menting that strategy; and 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy. 
‘‘(B) CONSULTATION WITH OTHER AGEN-
CIES.—Before the submission of the National 
Drug Control Strategy or annual supplement 
required under section 1005(d), as applicable, 
the United States Interdiction Coordinator shall 
issue the National Interdiction Command and 
Control Plan, in consultation with the other 
members of the Interdiction Committee de-
scribed in subsection (b). 
‘‘(C) REPORT TO CONGRESS.—On or be-
fore September 1 of each year, the Director, 
through the United States Interdiction Coordi-
nator, shall provide to the appropriate congres-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00088
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
sional committees, to the Committee on Armed 
Services and the Committee on Homeland Secu-
rity of the House of Representatives, and to the 
Committee on Homeland Security and Govern-
mental Affairs and the Committee on Armed 
Services of the Senate, a report that— 
‘‘(i) includes— 
‘‘(I) a copy of that year’s Na-
tional 
Interdiction 
Command 
and 
Control Plan; 
‘‘(II) information for the previous 
10 years regarding the number and 
type of seizures of drugs by each Na-
tional Drug Control Program Agency 
conducting drug interdiction activities 
and statistical information on the geo-
graphic areas of such seizures; and 
‘‘(III) information for the pre-
vious 10 years regarding the number 
of air and maritime patrol hours un-
dertaken by each National Drug Con-
trol Program Agency conducting drug 
interdiction activities and statistical 
information on the geographic areas 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00089
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
in which such patrol hours took place; 
and 
‘‘(ii) may include recommendations 
about changes to existing agency authori-
ties or laws governing interagency relation-
ships. 
‘‘(D) CLASSIFIED
ANNEX.—The report 
submitted pursuant to subparagraph (C) may 
include a classified annex. 
‘‘(b) INTERDICTION COMMITTEE.— 
‘‘(1) IN
GENERAL.—The Interdiction Com-
mittee shall meet to— 
‘‘(A) discuss and resolve issues related to 
the coordination, oversight, and integration of 
international, border, and domestic drug inter-
diction efforts in support of the National Drug 
Control Strategy; 
‘‘(B) review the annual National Interdic-
tion Command and Control Plan, and provide 
advice to the Director and the United States 
Interdiction Coordinator concerning that plan; 
and 
‘‘(C) provide such other advice to the Di-
rector concerning drug interdiction strategy and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00090
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
policies as the committee determines is appro-
priate. 
‘‘(2) CHAIR.—The Director shall designate one 
of the members of the Interdiction Committee to 
serve as Chair. 
‘‘(3) MEETINGS.—The members of the Interdic-
tion Committee shall meet, in person and not 
through any delegate or representative, at least once 
per calendar year, before June 1. At the call of the 
Director or the Chair, the Interdiction Committee 
may hold additional meetings, which shall be at-
tended by the members in person, or through such 
delegates or representatives as the members may 
choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the Chair of the Interdiction Committee 
shall submit to the Director and to the appropriate 
congressional committees a report describing the re-
sults of the meetings and any significant findings of 
the committee during the previous 12 months. Such 
report may include a classified annex. 
‘‘§ 1012. Treatment coordinator 
‘‘(a) UNITED STATES TREATMENT COORDINATOR.— 
‘‘(1) IN
GENERAL.—The Director shall des-
ignate or appoint a noncareer appointee in the Sen-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00091
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
ior Executive Service or a career appointee at the 
GS–15 level (or equivalent) or above as the United 
States Treatment Coordinator to perform the re-
sponsibilities of that position described in paragraph 
(2) and such other duties as may be determined by 
the Director with respect to coordination of efforts 
to expand the availability of substance use disorder 
treatment with the goal of eliminating the unmet 
treatment need. 
‘‘(2) RESPONSIBILITIES.—The United States 
Treatment Coordinator shall be responsible to the 
Director for— 
‘‘(A) coordinating the activities of the Na-
tional Drug Control Program Agencies under-
taken to expand the availability of evidence- 
based substance use disorder treatment to en-
sure consistency with the National Drug Con-
trol Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before September 1 of each 
year and in accordance with paragraph (4), a 
National Treatment Plan to ensure the coordi-
nation and consistency described in subpara-
graph (A); 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00092
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(C) assessing the sufficiency of Federal 
resources directed to substance use disorder 
treatment by the relevant National Drug Con-
trol Program Agencies; 
‘‘(D) encouraging the adoption by all sub-
stance use disorder treatment providers of evi-
dence-based standards to guide all aspects of 
treatment provided; and 
‘‘(E) advising the Director on the efforts 
of each National Drug Control Program Agency 
to implement the National Treatment Plan. 
‘‘(3) STAFF.—The Director shall assign such 
permanent staff of the Office of the United States 
Treatment Coordinator as the Director determines 
to be appropriate to assist the United States Treat-
ment Coordinator to carry out the responsibilities 
described in paragraph (2), and may request that 
appropriate National Drug Control Program Agen-
cies detail or assign staff to assist in carrying out 
such responsibilities. 
‘‘(4) NATIONAL TREATMENT PLAN.— 
‘‘(A) PURPOSES.—The National Treatment 
Plan— 
‘‘(i) shall identify the unmet need for 
treatment for evidence-based substance use 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00093
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
disorders and set forth the Government’s 
strategy for closing the gap between avail-
able and needed treatment through all 
sources; 
‘‘(ii) shall describe the specific roles 
and responsibilities of the relevant Na-
tional Drug Control Program Agencies for 
implementing that strategy; 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy; 
‘‘(iv) shall identify the resources, in-
cluding private sources, required to elimi-
nate the unmet need for evidence-based 
substance use disorder treatment; and 
‘‘(v) may include recommendations 
about changes to existing agency authori-
ties or laws governing interagency relation-
ships. 
‘‘(B) CONSULTATION WITH OTHER AGEN-
CIES.—Before the submission of the National 
Treatment Strategy or annual supplement re-
quired under section 1005(d), as applicable, the 
United States Treatment Coordinator shall 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00094
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
issue the National Treatment Plan, in consulta-
tion with the other members of the Treatment 
Committee described in subsection (b). 
‘‘(C) REPORT TO CONGRESS.—On or be-
fore September 1 of each year, the Director, 
through the United States Treatment Coordi-
nator, shall provide to the appropriate congres-
sional committees a report that includes a copy 
of that year’s National Treatment Plan. 
‘‘(b) TREATMENT COMMITTEE.— 
‘‘(1) IN GENERAL.—The Treatment Committee 
shall meet to— 
‘‘(A) review and discuss the adequacy of 
evidence-based substance use disorder treat-
ment as well as the unmet need for treatment; 
‘‘(B) review and discuss the status of the 
implementation of the National Treatment 
Plan; and 
‘‘(C) provide such other advice to the Di-
rector concerning substance use disorder treat-
ment initiatives as the committee determines is 
appropriate. 
‘‘(2) CHAIR.—The Director shall designate one 
of the members of the Treatment Committee to 
serve as Chair. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00095
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(3) MEETINGS.—The members of the Treat-
ment Committee shall meet, in person and not 
through any delegate or representative, at least once 
per calendar year, before June 1. At the call of the 
Director or the Chair, the Treatment Committee 
may hold additional meetings, which shall be at-
tended by the members in person, or through such 
delegates or representatives as the members may 
choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the Chair of the Treatment Committee 
shall submit to the Director and to the appropriate 
congressional committees a report describing the re-
sults of the meetings and any significant findings of 
the committee during the previous 12 months. Such 
report may include a classified annex. 
‘‘§ 1013. Critical information coordination 
‘‘(a) NATIONAL DRUG CONTROL FUSION CENTER.— 
‘‘(1) ESTABLISHMENT.—The Director shall, in 
consultation with the head of each National Drug 
Control Program Agency, designate an agency to es-
tablish a National Drug Control Fusion Center (re-
ferred to in this section as the ‘Center’). The Center 
shall operate under the authority of the Director and 
shall work with the National Drug Control Program 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00096
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
Agencies to collect, compile, analyze, and facilitate 
the sharing of data on the use of illicit drugs, treat-
ment for substance use disorder, and interdiction of 
illicit drugs. The Center shall be considered a ‘statis-
tical agency or unit’, as that term is defined in sec-
tion 502 of the Confidential Information Protection 
and Statistical Efficiency Act of 2002 (44 U.S.C. 
3501 note) and shall have the necessary independ-
ence to ensure any data or information acquired by 
an agency under a pledge of confidentiality and for 
exclusively statistical purposes is used exclusively for 
statistical purposes. 
‘‘(2) CENTER DIRECTOR.—There shall be at the 
head of the Center a Center Director who shall be 
appointed by the Director from among individuals 
qualified and distinguished in data governance and 
statistical analysis. 
‘‘(3) DATA COMPILATION.—The Director, act-
ing through the Center Director, shall do the fol-
lowing: 
‘‘(A) Coordinate data collection activities 
among the National Drug Control Program 
Agencies. 
‘‘(B) Collect information not otherwise col-
lected by National Drug Control Program 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00097
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(A) ESTABLISHMENT.—The Center Di-
rector may establish a toxicology screening pro-
gram that engages in— 
‘‘(i) secondary analysis of urine sam-
ples that would otherwise be discarded 
by— 
‘‘(I) hospitals and substance use 
disorder treatment programs; 
‘‘(II) correctional facilities, book-
ing sites, probation programs, drug 
courts, and related facilities; and 
‘‘(III) coroners and medical ex-
aminers; and 
‘‘(ii) analysis of other physical sam-
ples, as determined by the Center Director 
to be valuable for understanding the preva-
lence of any illicit drug. 
‘‘(B) DE-IDENTIFICATION
OF
INFORMA-
TION.—The Center Director shall ensure that 
no samples have any personally identifiable in-
formation prior to collection. 
‘‘(C) LIMITATION ON USE.—No data ob-
tained from analysis conducted under this para-
graph may be used as evidence in any pro-
ceeding. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00099
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
100 
HR 5925 RFS 
‘‘(D) STATE PROGRAM.—The Center Di-
rector may establish a program that enables 
States and local jurisdictions to submit up to 
20 urine samples per year for toxicology anal-
ysis for the purposes of identifying substances 
present in individuals who have suffered fatal 
drug overdoses. 
‘‘(5) AUTHORITY TO CONTRACT.—The Director 
may award contracts, enter into interagency agree-
ments, manage individual projects, and conduct 
other operational activities under this subsection. 
‘‘(b) CRITICAL DRUG CONTROL INFORMATION AND 
EVIDENCE PLAN.— 
‘‘(1) IN
GENERAL.—Not later than the first 
Monday in February of each year, the Director shall 
submit to Congress a systematic plan for increasing 
data collection to enable real-time surveillance of 
drug control threats, developing analysis and moni-
toring capabilities, and identifying and addressing 
policy questions relevant to the National Drug Con-
trol Policy, Strategy, and Program. Such plan shall 
be made available on the public online portal of the 
Office, shall cover at least a 4-year period beginning 
with the first fiscal year following the fiscal year in 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00100
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
101 
HR 5925 RFS 
which the plan is submitted and published, and con-
tain the following: 
‘‘(A) A list of policy-relevant questions for 
which the Director and each National Drug 
Control Program Agency intends to develop evi-
dence to support the National Drug Control 
Program and Strategy. 
‘‘(B) A list of data the Director and each 
National Drug Control Program Agency intends 
to collect, use, or acquire to facilitate the use of 
evidence in drug control policymaking and mon-
itoring. 
‘‘(C) A list of methods and analytical ap-
proaches that may be used to develop evidence 
to support the National Drug Control Program 
and Strategy and related policy. 
‘‘(D) A list of any challenges to developing 
evidence to support policymaking, including any 
barriers to accessing, collecting, or using rel-
evant data. 
‘‘(E) A description of the steps the Direc-
tor and the head of each National Drug Control 
Program Agency will take to effectuate the 
plan. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00101
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
102 
HR 5925 RFS 
‘‘(F) Any other relevant information as de-
termined by the Director. 
‘‘(2) CONSULTATION.—In developing the plan 
required under paragraph (1), the Director shall 
consult with the following: 
‘‘(A) The public. 
‘‘(B) Any evaluation or analysis units and 
personnel of the Office. 
‘‘(C) Office officials responsible for imple-
menting privacy policy. 
‘‘(D) Office officials responsible for data 
governance. 
‘‘(E) The appropriate congressional com-
mittees. 
‘‘(F) Any other individual or entity as de-
termined by the Director. 
‘‘(c) EVIDENCE-BASED POLICY.— 
‘‘(1) HARM REDUCTION PROGRAMS.—When de-
veloping the national drug control policy, any policy 
of the Director, including policies relating to syringe 
exchange programs for intravenous drug users, shall 
be based on the best available medical and scientific 
evidence regarding the effectiveness of such policy in 
promoting individual health, preventing the spread 
of infectious disease and the impact of such policy 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00102
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
103 
HR 5925 RFS 
on drug addiction and use. In making any policy re-
lating to harm reduction programs, the Director 
shall consult with the National Institutes of Health 
and the National Academy of Sciences. 
‘‘(2) FUND RESTRICTION FOR THE LEGALIZA-
TION OF CONTROLLED SUBSTANCES.—The Director 
shall ensure that no Federal funds appropriated to 
the Office shall be expended for any study or con-
tract relating to the legalization (for a medical use 
or any other use) for which a listing in schedule I 
is in effect under section 202 of the Controlled Sub-
stances Act (21 U.S.C. 812). 
‘‘(d) DRUG CONTROL DATA DASHBOARD.— 
‘‘(1) ESTABLISHMENT.—The Director, in con-
sultation with the Center Director, shall establish 
and maintain a data dashboard on the online portal 
of the Office to be known as the ‘Drug Control Data 
Dashboard’. The Director shall ensure the user 
interface of the dashboard is constructed with mod-
ern design standards. To the extent practicable, the 
data made available on the dashboard shall be pub-
licly available in a machine-readable format and 
searchable by year, agency, drug, and location. 
‘‘(2) DATA.—The data included in the Drug 
Control Data Dashboard shall be updated quarterly 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00103
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
104 
HR 5925 RFS 
to the extent practicable, but not less frequently 
than annually and shall include, at a minimum, the 
following: 
‘‘(A) For each substance identified under 
section 1005(c)(1)(A)(i)— 
‘‘(i) the total amount seized and dis-
rupted in the calendar year and each of 
the previous 3 calendar years, including to 
the extent practicable the amount seized by 
State, local, and Tribal governments; 
‘‘(ii) the known and estimated flows 
into the United States from all sources in 
the calendar year and each of the previous 
3 calendar years; 
‘‘(iii) the total amount of known flows 
that could not be interdicted or disrupted 
in the calendar year and each of the pre-
vious 3 calendar years; 
‘‘(iv) the known and estimated levels 
of domestic production in the calendar year 
and each of the previous 3 calendar years, 
including the levels of domestic production 
if the drug is a prescription drug, as deter-
mined under the Federal Food, Drug, and 
Cosmetic Act, for which a listing is in ef-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00104
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
105 
HR 5925 RFS 
fect under section 202 of the Controlled 
Substances Act (21 U.S.C. 812); 
‘‘(v) the average street price for the 
calendar year and the highest known street 
price during the preceding 10-year period; 
and 
‘‘(vi) to the extent practicable, related 
prosecutions by State, local, and Tribal 
governments. 
‘‘(B) For the calendar year and each of the 
previous 3 years data sufficient to show, 
disaggregated by State and, to the extent fea-
sible, by region within a State, county, or city, 
the following: 
‘‘(i) The number of fatal and non- 
fatal overdoses caused by each drug identi-
fied under subparagraph (A)(i). 
‘‘(ii) The prevalence of substance use 
disorders. 
‘‘(iii) The number of individuals who 
have received substance use disorder treat-
ment, including medication assisted treat-
ment, for a substance use disorder, includ-
ing treatment provided through publicly-fi-
nanced health care programs. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00105
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
106 
HR 5925 RFS 
‘‘(iv) The extent of the unmet need 
for substance use disorder treatment, in-
cluding the unmet need for medication-as-
sisted treatment. 
‘‘(C) Data sufficient to show the extent of 
prescription drug diversion, trafficking, and 
misuse in the calendar year and each of the 
previous 3 calendar years. 
‘‘(D) Any quantifiable measures the Direc-
tor determines to be appropriate to detail 
progress toward the achievement of the goals of 
the National Drug Control Strategy. 
‘‘(e) ACCESS TO INFORMATION.— 
‘‘(1) IN GENERAL.—Upon the request of the 
Director, the head of any National Drug Control 
Program Agency shall cooperate with and provide to 
the Director any statistics, studies, reports, and 
other information prepared or collected by the agen-
cy concerning the responsibilities of the agency 
under the National Drug Control Strategy that re-
late to— 
‘‘(A) drug control; or 
‘‘(B) the manner in which amounts made 
available to that agency for drug control are 
being used by that agency. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00106
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
107 
HR 5925 RFS 
‘‘(2) PROTECTION OF INTELLIGENCE INFORMA-
TION.— 
‘‘(A) IN GENERAL.—The authorities con-
ferred on the Office and the Director by this 
chapter shall be exercised in a manner con-
sistent with provisions of the National Security 
Act of 1947 (50 U.S.C. 401 et seq.). The Di-
rector of National Intelligence shall prescribe 
such regulations as may be necessary to protect 
information provided pursuant to this chapter 
regarding intelligence sources and methods. 
‘‘(B) DUTIES OF DIRECTOR.—The Director 
of National Intelligence and the Director of the 
Central Intelligence Agency shall, to the max-
imum extent practicable in accordance with 
subparagraph (A), render full assistance and 
support to the Office and the Director. 
‘‘(3) REQUIRED
REPORTS
FROM
NATIONAL 
DRUG CONTROL PROGRAM AGENCIES.—The head of 
each National Drug Control Program Agency shall 
submit to the Director such information and reports 
as requested from such National Drug Control Pro-
gram Agency by the Director, which shall include 
from the appropriate National Drug Control Pro-
gram Agencies: 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00107
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
108 
HR 5925 RFS 
‘‘(A) Not later than July 1 of each year, 
the head of a National Drug Control Program 
Agency designated by the Director shall submit 
to the Director and the appropriate congres-
sional committees an assessment of the quantity 
of illegal drug cultivation and manufacturing in 
the United States on lands owned or under the 
jurisdiction of their respective agencies that was 
seized or eradicated by their personnel during 
the preceding calendar year. 
‘‘(B) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding— 
‘‘(i) the number and type of seizures 
of drugs by each component of the agency 
seizing drugs, as well as statistical infor-
mation on the geographic areas of such 
seizures; and 
‘‘(ii) the number of air and maritime 
patrol hours primarily dedicated to drug 
supply reduction missions undertaken by 
each component of the agency. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00108
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
109 
HR 5925 RFS 
‘‘(C) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding 
the number of air and maritime patrol hours 
primarily dedicated to drug supply reduction 
missions undertaken by each component of the 
agency. 
‘‘(D) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding 
the number and type of— 
‘‘(i) arrests for drug violations; 
‘‘(ii) prosecutions by United States 
Attorneys for drug violations; and 
‘‘(iii) seizures of drugs by each com-
ponent of the Department of Justice seiz-
ing drugs, as well as statistical information 
on the geographic areas of such seizures. 
‘‘(f) DATA EXCHANGE STANDARDS FOR IMPROVED 
INTEROPERABILITY.— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00109
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
110 
HR 5925 RFS 
‘‘(1) INTERAGENCY AND INTERGOVERNMENTAL 
DESIGNATION AND USE OF DATA EXCHANGE STAND-
ARDS WORKING GROUP.—The Director shall estab-
lish a working group of National Drug Control Pro-
gram Agencies, State, local and Tribal government 
health and law enforcement agencies, and data gov-
ernance experts to develop consensus data exchange 
standards for necessary categories of information 
that allow effective electronic exchange of informa-
tion between States, between State agencies, be-
tween States and National Drug Control Program 
Agencies, and any other drug control relevant data 
exchange. 
‘‘(2) DATA
EXCHANGE
STANDARDS
MUST
BE 
NONPROPRIETARY AND INTEROPERABLE.—The data 
exchange standards developed under paragraph (1) 
shall, to the extent practicable, be nonproprietary 
and interoperable. 
‘‘(3) OTHER
REQUIREMENTS.—In developing 
data exchange standards under this subsection, the 
working group shall, to the extent practicable, incor-
porate— 
‘‘(A) interoperable standards developed 
and maintained by an international voluntary 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00110
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
111 
HR 5925 RFS 
consensus standards body, as defined by the Of-
fice of Management and Budget; 
‘‘(B) interoperable standards developed 
and maintained by intergovernmental partner-
ships; and 
‘‘(C) interoperable standards developed 
and maintained by Federal entities with author-
ity over contracting and financial assistance. 
‘‘(4) DATA EXCHANGE STANDARDS FOR FED-
ERAL REPORTING.— 
‘‘(A) DESIGNATION.—The Director may, in 
consultation with the working group established 
under this subsection, National Drug Control 
Program Agencies, and State, local, and Tribal 
governments, designate data exchange stand-
ards to govern Federal reporting and exchange 
requirements for National Drug Control Pro-
grams, as appropriate. 
‘‘(B) REQUIREMENTS.—The data exchange 
reporting standards designated under subpara-
graph (A) shall, to the extent practicable— 
‘‘(i) incorporate a widely accepted, 
nonproprietary, searchable, machine-read-
able format; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00111
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
112 
HR 5925 RFS 
‘‘(ii) be consistent with and implement 
applicable accounting principles; 
‘‘(iii) be implemented in a manner 
that is cost-effective and improves program 
efficiency and effectiveness; and 
‘‘(iv) be capable of being continually 
upgraded as necessary. 
‘‘(C) 
INCORPORATION
OF
NONPROPRI-
ETARY
STANDARDS.—In designating data ex-
change standards under this paragraph, the Di-
rector shall, to the extent practicable, incor-
porate existing nonproprietary standards. 
‘‘(D) RULE OF CONSTRUCTION.—Nothing 
in this paragraph shall be construed to require 
a change to existing data exchange standards 
for Federal reporting about a program referred 
to in this section, if the head of the agency re-
sponsible for administering the program finds 
the standards to be effective and efficient. 
‘‘(5) TERMINATION.—The working group estab-
lished under paragraph (1) shall terminate not ear-
lier than 60 days after the public notification of ter-
mination by the Director. 
‘‘(g) ANNUAL DATA COLLECTION AND DISSEMINA-
TION REQUIREMENTS.— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00112
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
113 
HR 5925 RFS 
‘‘(1) IN GENERAL.—The Director shall collect 
and disseminate, as appropriate, such information as 
the Director determines is appropriate, but not less 
than the information described in this subsection. To 
the extent practicable, the data shall be publicly 
available in a machine-readable format on the Drug 
Control Data Dashboard, be searchable by year, 
agency, drug, and location, and cover not less than 
the previous 10-year period. 
‘‘(2) PREPARATION AND DISSEMINATION OF IN-
FORMATION.—The Director shall prepare and dis-
seminate the following: 
‘‘(A) An assessment of current illicit drug 
use (including inhalants and steroids) and avail-
ability, impact of illicit drug use, and treatment 
availability, which assessment shall include— 
‘‘(i) estimates of drug prevalence and 
frequency of use as measured by national, 
State, and local surveys of illicit drug use 
and by other special studies of non-
dependent and dependent illicit drug use; 
‘‘(ii) illicit drug use in the workplace 
and the productivity lost by such use; and 
‘‘(iii) illicit drug use by arrestees, pro-
bationers, and parolees. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00113
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
114 
HR 5925 RFS 
‘‘(B) An assessment of the reduction of il-
licit drug availability, for each drug identified 
under section 1005(c)(1)(A)(i), as measured 
by— 
‘‘(i) the quantities of such drug avail-
able for consumption in the United States; 
‘‘(ii) the amount of such drug enter-
ing the United States; 
‘‘(iii) the number of illicit drug manu-
facturing laboratories seized and destroyed 
of each such drug and the number of hec-
tares cultivated and destroyed domestically 
and in other countries of such drug; 
‘‘(iv) the number of metric tons of 
such drug seized; and 
‘‘(v) changes in the price and purity 
of such drug. 
‘‘(C) An assessment of the reduction of the 
consequences of illicit drug use and availability, 
which shall include— 
‘‘(i) the cost of treating substance use 
disorder in the United States, such as the 
quantity of illicit drug-related services pro-
vided; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00114
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
115 
HR 5925 RFS 
‘‘(ii) the annual national health care 
cost of illicit drug use; and 
‘‘(iii) the extent of illicit drug-related 
crime and criminal activity. 
‘‘(D) A determination of the status of sub-
stance use disorder treatment in the United 
States, by assessing— 
‘‘(i) public and private treatment utili-
zation; and 
‘‘(ii) the number of illicit drug users 
the Director estimates meet diagnostic cri-
teria for treatment. 
‘‘§ 1014. Authorization of appropriations 
‘‘There are authorized to be appropriated to carry out 
this chapter, except as otherwise specified, to remain avail-
able until expended, $18.4 million for each of fiscal years 
2019 through 2023. 
‘‘SUBCHAPTER II—DRUG-FREE COMMUNITIES 
SUPPORT PROGRAM 
‘‘§ 1021. Establishment of drug-free communities sup-
port program 
‘‘(a) ESTABLISHMENT.—The Director shall establish 
a program to support communities in the development and 
implementation of comprehensive, long-term plans and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00115
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
116 
HR 5925 RFS 
programs to prevent and treat substance use and misuse 
among youth. 
‘‘(b) PROGRAM.—In carrying out the Program, the 
Director shall— 
‘‘(1) make and track grants to grant recipients; 
‘‘(2) provide for technical assistance and train-
ing, data collection, and dissemination of informa-
tion on state-of-the-art practices that the Director 
determines to be effective in reducing substance use; 
and 
‘‘(3) provide for the general administration of 
the Program. 
‘‘(c) ADMINISTRATION.—The Director shall appoint 
an Administrator to carry out the Program. 
‘‘(d) CONTRACTING.—The Director may employ any 
necessary staff and may enter into contracts or agree-
ments with National Drug Control Program Agencies, in-
cluding interagency agreements, to delegate authority for 
the execution of grants and for such other activities nec-
essary to carry out this chapter. 
‘‘§ 1022. Program authorization 
‘‘(a) GRANT ELIGIBILITY.—To be eligible to receive 
an initial grant or a renewal grant under this subchapter, 
a coalition shall meet each of the following criteria: 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00116
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
117 
HR 5925 RFS 
‘‘(1) APPLICATION.—The coalition shall submit 
an application to the Administrator in accordance 
with section 1023(a)(2). 
‘‘(2) MAJOR SECTOR INVOLVEMENT.— 
‘‘(A) IN
GENERAL.—The coalition shall 
consist of one or more representatives of each 
of the following categories: 
‘‘(i) Youth. 
‘‘(ii) Parents. 
‘‘(iii) Businesses. 
‘‘(iv) The media. 
‘‘(v) Schools. 
‘‘(vi) Organizations serving youth. 
‘‘(vii) Law enforcement. 
‘‘(viii) Religious or fraternal organiza-
tions. 
‘‘(ix) Civic and volunteer groups. 
‘‘(x) Health care professionals. 
‘‘(xi) State, local, or Tribal govern-
mental agencies with expertise in the field 
of substance use prevention or substance 
use disorders (including, if applicable, the 
State authority with primary authority for 
substance use and misuse). 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00117
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
118 
HR 5925 RFS 
‘‘(xii) Other organizations involved in 
reducing the prevalence of substance use 
and misuse or substance use disorders. 
‘‘(B) ELECTED OFFICIALS.—If feasible, in 
addition to representatives from the categories 
listed in subparagraph (A), the coalition shall 
have an elected official (or a representative of 
an elected official) from— 
‘‘(i) the Federal Government; and 
‘‘(ii) the government of the appro-
priate State and political subdivision there-
of or the governing body or an Indian tribe 
(as that term is defined in section 4(e) of 
the Indian Self-Determination Act (25 
U.S.C. 5304)). 
‘‘(C) 
REPRESENTATION.—An 
individual 
who is a member of the coalition may serve on 
the coalition as a representative of not more 
than one category listed under subparagraph 
(A). 
‘‘(3) COMMITMENT.—The coalition shall dem-
onstrate, to the satisfaction of the Administrator— 
‘‘(A) that the representatives of the coali-
tion have worked together on substance use and 
misuse reduction initiatives, which, at a min-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00118
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
119 
HR 5925 RFS 
imum, includes initiatives that target drugs de-
scribed in section 1027(6)(A), for a period of 
not less than 6 months, acting through entities 
such as task forces, subcommittees, or commu-
nity boards; and 
‘‘(B) substantial participation from volun-
teer leaders in the community involved (espe-
cially in cooperation with individuals involved 
with youth such as parents, teachers, coaches, 
youth workers, and members of the clergy). 
‘‘(4) MISSION AND STRATEGIES.—The coalition 
shall, with respect to the community involved— 
‘‘(A) have as its principal mission the re-
duction of illegal drug use, which, at a min-
imum, includes the use of illegal drugs de-
scribed in section 1027(6)(A), in a comprehen-
sive and long-term manner, with a primary 
focus on youth in the community; 
‘‘(B) describe and document the nature 
and extent of the substance use and misuse 
problem, which, at a minimum, includes the use 
and misuse of drugs described in section 
1027(6)(A), in the community; 
‘‘(C)(i) provide a description of substance 
use and misuse prevention and treatment pro-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00119
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
120 
HR 5925 RFS 
grams and activities, which, at a minimum, in-
cludes programs and activities relating to the 
use and misuse of drugs described in section 
1027(6)(A), in existence at the time of the 
grant application; and 
‘‘(ii) identify substance use and misuse 
programs and service gaps, which, at a min-
imum, includes programs and gaps relating to 
the use and misuse of drugs described in sec-
tion 1027(6)(A), in the community; 
‘‘(D) develop a strategic plan to reduce 
substance use and misuse among youth, which, 
at a minimum, includes the use and misuse of 
drugs described in section 1027(6)(A), in a 
comprehensive and long-term fashion; and 
‘‘(E) work to develop a consensus regard-
ing the priorities of the community to combat 
substance use and misuse among youth, which, 
at a minimum, includes the use and misuse of 
drugs described in section 1027(6)(A). 
‘‘(5) SUSTAINABILITY.—The coalition shall 
demonstrate that the coalition is an ongoing concern 
by demonstrating that the coalition— 
‘‘(A) is— 
‘‘(i)(I) a nonprofit organization; or 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00120
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
121 
HR 5925 RFS 
‘‘(II) an entity that the Administrator 
determines to be appropriate; or 
‘‘(ii) part of, or is associated with, an 
established legal entity; 
‘‘(B) receives financial support (including, 
in the discretion of the Administrator, in-kind 
contributions) from non-Federal sources; and 
‘‘(C) has a strategy to solicit substantial fi-
nancial support from non-Federal sources to en-
sure that the coalition and the programs oper-
ated by the coalition are self-sustaining. 
‘‘(6) ACCOUNTABILITY.—The coalition shall— 
‘‘(A) establish a system to measure and re-
port outcomes— 
‘‘(i) consistent with common indica-
tors and evaluation protocols established 
by the Administrator; and 
‘‘(ii) approved by the Administrator; 
‘‘(B) conduct— 
‘‘(i) for an initial grant under this 
subchapter, an initial benchmark survey of 
drug use among youth (or use local sur-
veys or performance measures available or 
accessible in the community at the time of 
the grant application); and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00121
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
122 
HR 5925 RFS 
‘‘(ii) biennial surveys (or incorporate 
local surveys in existence at the time of the 
evaluation) to measure the progress and 
effectiveness of the coalition; and 
‘‘(C) provide assurances that the entity 
conducting an evaluation under this paragraph, 
or from which the coalition receives informa-
tion, has experience— 
‘‘(i) in gathering data related to sub-
stance use and misuse among youth; or 
‘‘(ii) in evaluating the effectiveness of 
community anti-drug coalitions. 
‘‘(7) ADDITIONAL
CRITERIA.—The Director 
shall not impose any eligibility criteria on new appli-
cants or renewal grantees not provided in this chap-
ter. 
‘‘(b) GRANT AMOUNTS.— 
‘‘(1) IN GENERAL.— 
‘‘(A) GRANTS.— 
‘‘(i) IN GENERAL.—Subject to clause 
(iv), for a fiscal year, the Administrator 
may grant to an eligible coalition under 
this paragraph, an amount not to exceed 
the amount of non-Federal funds raised by 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00122
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
123 
HR 5925 RFS 
the coalition, including in-kind contribu-
tions, for that fiscal year. 
‘‘(ii) SUSPENSION
OF
GRANTS.—If 
such grant recipient fails to continue to 
meet the criteria specified in subsection 
(a), the Administrator may suspend the 
grant, after providing written notice to the 
grant recipient and an opportunity to ap-
peal. 
‘‘(iii) RENEWAL GRANTS.—Subject to 
clause (iv), the Administrator may award a 
renewal grant to a grant recipient under 
this subparagraph for each fiscal year fol-
lowing the fiscal year for which an initial 
grant is awarded, in an amount not to ex-
ceed the amount of non-Federal funds 
raised by the coalition, including in-kind 
contributions, for that fiscal year, during 
the 4-year period following the period of 
the initial grant. 
‘‘(iv) LIMITATION.—The amount of a 
grant award under this subparagraph may 
not exceed $125,000 for a fiscal year. 
‘‘(B) COALITION AWARDS.— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00123
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
124 
HR 5925 RFS 
‘‘(i) IN
GENERAL.—Except as pro-
vided in clause (ii), the Administrator may, 
with respect to a community, make a grant 
to one eligible coalition that represents 
that community. 
‘‘(ii) EXCEPTION.—The Administrator 
may make a grant to more than one eligi-
ble coalition that represents a community 
if— 
‘‘(I) the eligible coalitions dem-
onstrate that the coalitions are col-
laborating with one another; and 
‘‘(II) each of the coalitions has 
independently met the requirements 
set forth in subsection (a). 
‘‘(2) RURAL COALITION GRANTS.— 
‘‘(A) IN GENERAL.— 
‘‘(i) IN
GENERAL.—In addition to 
awarding grants under paragraph (1), to 
stimulate the development of coalitions in 
sparsely populated and rural areas, the 
Administrator may award a grant in ac-
cordance with this section to a coalition 
that represents a county with a population 
that does not exceed 30,000 individuals. In 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00124
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
125 
HR 5925 RFS 
awarding a grant under this paragraph, 
the Administrator may waive any require-
ment under subsection (a) if the Adminis-
trator considers that waiver to be appro-
priate. 
‘‘(ii) 
MATCHING
REQUIREMENT.— 
Subject to subparagraph (C), for a fiscal 
year, the Administrator may grant to an 
eligible coalition under this paragraph, an 
amount not to exceed the amount of non- 
Federal funds raised by the coalition, in-
cluding in-kind contributions, for that fis-
cal year. 
‘‘(iii) SUSPENSION
OF
GRANTS.—If 
such grant recipient fails to continue to 
meet any criteria specified in subsection 
(a) that has not been waived by the Ad-
ministrator pursuant to clause (i), the Ad-
ministrator may suspend the grant, after 
providing written notice to the grant re-
cipient and an opportunity to appeal. 
‘‘(B) RENEWAL
GRANTS.—The Adminis-
trator may award a renewal grant to an eligible 
coalition that is a grant recipient under this 
paragraph for each fiscal year following the fis-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00125
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
126 
HR 5925 RFS 
cal year for which an initial grant is awarded, 
in an amount not to exceed the amount of non- 
Federal funds raised by the coalition, including 
in-kind contributions, during the 4-year period 
following the period of the initial grant. 
‘‘(C) LIMITATIONS.— 
‘‘(i) AMOUNT.—The amount of a 
grant award under this paragraph shall 
not exceed $125,000 for a fiscal year. 
‘‘(ii) AWARDS.—With respect to a 
county referred to in subparagraph (A), 
the Administrator may award a grant 
under this section to not more than one el-
igible coalition that represents the county. 
‘‘(3) ADDITIONAL GRANTS.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (F), the Administrator may award an ad-
ditional grant under this paragraph to an eligi-
ble coalition awarded a grant under paragraph 
(1) or (2) for any first fiscal year after the end 
of the 4-year period following the period of the 
initial grant under paragraph (1) or (2), as the 
case may be. 
‘‘(B) SCOPE
OF
GRANTS.—A coalition 
awarded a grant under paragraph (1) or (2), 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00126
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
127 
HR 5925 RFS 
including a renewal grant under such para-
graph, may not be awarded another grant 
under such paragraph, and is eligible for an ad-
ditional grant under this section only under this 
paragraph. 
‘‘(C) NO PRIORITY FOR APPLICATIONS.— 
The Administrator may not afford a higher pri-
ority in the award of an additional grant under 
this paragraph than the Administrator would 
afford the applicant for the grant if the appli-
cant were submitting an application for an ini-
tial grant under paragraph (1) or (2) rather 
than an application for a grant under this para-
graph. 
‘‘(D) RENEWAL GRANTS.—Subject to sub-
paragraph (F), the Administrator may award a 
renewal grant to a grant recipient under this 
paragraph for each of the fiscal years of the 4- 
fiscal-year period following the fiscal year for 
which the initial additional grant under sub-
paragraph (A) is awarded in an amount not to 
exceed amounts as follows: 
‘‘(i) For the first and second fiscal 
years of that 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00127
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
128 
HR 5925 RFS 
ing in-kind contributions, raised by the co-
alition for the applicable fiscal year is not 
less than 125 percent of the amount 
awarded. 
‘‘(ii) For the third and fourth fiscal 
years of that 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
ing in-kind contributions, raised by the co-
alition for the applicable fiscal year is not 
less than 150 percent of the amount 
awarded. 
‘‘(E) SUSPENSION.—If a grant recipient 
under this paragraph fails to continue to meet 
the criteria specified in subsection (a), the Ad-
ministrator may suspend the grant, after pro-
viding written notice to the grant recipient and 
an opportunity to appeal. 
‘‘(F) LIMITATION.—The amount of a grant 
award under this paragraph may not exceed 
$125,000 for a fiscal year. 
‘‘(4) PROCESS
FOR
SUSPENSION.—A grantee 
shall not be suspended or terminated under para-
graph (1)(A)(ii), (2)(A)(iii), or (3)(E) unless that 
grantee is afforded a fair, timely, and independent 
appeal prior to such suspension or termination. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00128
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
129 
HR 5925 RFS 
‘‘(c) TREATMENT OF FUNDS FOR COALITIONS REP-
RESENTING CERTAIN ORGANIZATIONS.—Funds appro-
priated for the substance use and misuse activities of a 
coalition that includes a representative of the Bureau of 
Indian Affairs, the Indian Health Service, or a Tribal gov-
ernment agency with expertise in the field of substance 
use prevention may be counted as non-Federal funds 
raised by the coalition for purposes of this section. 
‘‘(d) PRIORITY IN AWARDING GRANTS.—In awarding 
grants under subsection (b)(1)(A)(i), priority shall be 
given to a coalition serving economically disadvantaged 
areas. 
‘‘§ 1023. Information collection and dissemination 
with respect to grant recipients 
‘‘(a) COALITION INFORMATION.— 
‘‘(1) GENERAL AUDITING AUTHORITY.—For the 
purpose of audit and examination, the Adminis-
trator— 
‘‘(A) shall have access to any books, docu-
ments, papers, and records that are pertinent to 
any grant or grant renewal request under this 
subchapter; and 
‘‘(B) may periodically request information 
from a grant recipient to ensure that the grant 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00129
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
130 
HR 5925 RFS 
recipient meets the applicable criteria under 
section 1022(a). 
‘‘(2) APPLICATION
PROCESS.—The Adminis-
trator shall issue a request for proposal regarding, 
with respect to the grants awarded under section 
1022, the application process, grant renewal, and 
suspension or withholding of renewal grants. Each 
application under this paragraph shall be in writing 
and shall be subject to review by the Administrator. 
‘‘(3) REPORTING.—The Administrator shall, to 
the maximum extent practicable and in a manner 
consistent with applicable law, minimize reporting 
requirements by a grant recipient and expedite any 
application for a renewal grant made under this sub-
chapter. 
‘‘(b) DATA COLLECTION AND DISSEMINATION.— 
‘‘(1) IN
GENERAL.—The Administrator may 
collect data from— 
‘‘(A) national substance use and misuse or-
ganizations that work with eligible coalitions, 
community anti-drug coalitions, departments or 
agencies of the Federal Government, or State 
or local governments and the governing bodies 
of Indian Tribes; and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00130
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
131 
HR 5925 RFS 
‘‘(B) any other entity or organization that 
carries out activities that relate to the purposes 
of the Program. 
‘‘(2) ACTIVITIES OF ADMINISTRATOR.—The Ad-
ministrator may— 
‘‘(A) evaluate the utility of specific initia-
tives relating to the purposes of the Program; 
‘‘(B) conduct an evaluation of the Pro-
gram; and 
‘‘(C) disseminate information described in 
this subsection to— 
‘‘(i) eligible coalitions and other sub-
stance use prevention organizations; and 
‘‘(ii) the general public. 
‘‘(3) CONSULTATION.—The Administrator shall 
carry out activities under this subsection in consulta-
tion with the National Community Antidrug Coali-
tion Institute. 
‘‘(4) LIMITATION ON USE OF CERTAIN FUNDS 
FOR EVALUATION OF PROGRAM.—Amounts for ac-
tivities under paragraph (2)(B) may not be derived 
from amounts under section 1028(a) except for 
amounts that are available under section 1028(b) for 
administrative costs. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00131
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
132 
HR 5925 RFS 
‘‘§ 1024. Technical assistance and training 
‘‘(a) IN GENERAL.— 
‘‘(1) TECHNICAL
ASSISTANCE
AND
AGREE-
MENTS.—With respect to any grant recipient or 
other organization, the Administrator may— 
‘‘(A) offer technical assistance and train-
ing; and 
‘‘(B) enter into contracts and cooperative 
agreements. 
‘‘(2) COORDINATION OF PROGRAMS.—The Ad-
ministrator may facilitate the coordination of pro-
grams between a grant recipient and other organiza-
tions and entities. 
‘‘(b) TRAINING.—The Administrator may provide 
training to any representative designated by a grant re-
cipient in— 
‘‘(1) coalition building; 
‘‘(2) task force development; 
‘‘(3) mediation and facilitation, direct service, 
assessment and evaluation; or 
‘‘(4) any other activity related to the purposes 
of the Program. 
‘‘§ 1025. Supplemental grants for coalition mentoring 
activities 
‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 
Program, the Director may award an initial grant under 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00132
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
133 
HR 5925 RFS 
this subsection, and renewal grants under subsection (f), 
to any coalition awarded a grant under section 1022 that 
meets the criteria specified in subsection (d) in order to 
fund coalition mentoring activities by such coalition in 
support of the program. 
‘‘(b) TREATMENT WITH OTHER GRANTS.— 
‘‘(1) SUPPLEMENT.—A grant awarded to a coa-
lition under this section is in addition to any grant 
awarded to the coalition under section 1022. 
‘‘(2) REQUIREMENT FOR BASIC GRANT.—A coa-
lition may not be awarded a grant under this section 
for a fiscal year unless the coalition was awarded a 
grant or renewal grant under section 1022(b) for 
that fiscal year. 
‘‘(c) APPLICATION.—A coalition seeking a grant 
under this section shall submit to the Administrator an 
application for the grant in such form and manner as the 
Administrator may require. 
‘‘(d) CRITERIA.—A coalition meets the criteria speci-
fied in this subsection if the coalition— 
‘‘(1) has been in existence for at least 5 years; 
‘‘(2) has achieved, by or through its own ef-
forts, measurable results in the prevention and treat-
ment of substance use and misuse among youth; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00133
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
134 
HR 5925 RFS 
‘‘(3) has staff or members willing to serve as 
mentors for persons seeking to start or expand the 
activities of other coalitions in the prevention and 
treatment of substance use and misuse; 
‘‘(4) has demonstrable support from some mem-
bers of the community in which the coalition men-
toring activities to be supported by the grant under 
this section are to be carried out; and 
‘‘(5) submits to the Administrator a detailed 
plan for the coalition mentoring activities to be sup-
ported by the grant under this section. 
‘‘(e) USE OF GRANT FUNDS.—A coalition awarded 
a grant under this section shall use the grant amount for 
mentoring activities to support and encourage the develop-
ment of new, self-supporting community coalitions that 
are focused on the prevention and treatment of substance 
use and misuse in such new coalitions’ communities. The 
mentoring coalition shall encourage such development in 
accordance with the plan submitted by the mentoring coa-
lition under subsection (d)(5). 
‘‘(f) RENEWAL GRANTS.—The Administrator may 
make a renewal grant to any coalition awarded a grant 
under subsection (a), or a previous renewal grant under 
this subsection, if the coalition, at the time of application 
for such renewal grant— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00134
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
135 
HR 5925 RFS 
‘‘(1) continues to meet the criteria specified in 
subsection (d); and 
‘‘(2) has made demonstrable progress in the de-
velopment of one or more new, self-supporting com-
munity coalitions that are focused on the prevention 
and treatment of substance use and misuse. 
‘‘(g) GRANT AMOUNTS.— 
‘‘(1) IN GENERAL.—Subject to paragraphs (2) 
and (3), the total amount of grants awarded to a co-
alition under this section for a fiscal year may not 
exceed the amount of non-Federal funds raised by 
the coalition, including in-kind contributions, for 
that fiscal year. Funds appropriated for the sub-
stance use and misuse activities of a coalition that 
includes a representative of the Bureau of Indian 
Affairs, the Indian Health Service, or a Tribal gov-
ernment agency with expertise in the field of sub-
stance use prevention may be counted as non-Fed-
eral funds raised by the coalition. 
‘‘(2) INITIAL GRANTS.—The amount of the ini-
tial grant awarded to a coalition under subsection 
(a) may not exceed $75,000. 
‘‘(3) RENEWAL GRANTS.—The total amount of 
renewal grants awarded to a coalition under sub-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00135
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
136 
HR 5925 RFS 
section (f) for any fiscal year may not exceed 
$75,000. 
‘‘(h) FISCAL YEAR LIMITATION ON AMOUNT AVAIL-
ABLE
FOR GRANTS.—The total amount available for 
grants under this section, including renewal grants under 
subsection (f), in any fiscal year may not exceed the 
amount equal to 5 percent of the amount authorized to 
be appropriated by section 1028 for that fiscal year. 
‘‘(i) PRIORITY IN AWARDING INITIAL GRANTS.—In 
awarding initial grants under this section, priority shall 
be given to a coalition that expressly proposes to provide 
mentorship to a coalition or aspiring coalition serving eco-
nomically disadvantaged areas. 
‘‘§ 1026. Authorization for National Community Anti-
drug Coalition Institute 
‘‘(a) IN
GENERAL.—The Director shall, using 
amounts authorized to be appropriated by subsection (d), 
make a competitive grant to provide for the continuation 
of the National Community Anti-drug Coalition Institute. 
‘‘(b) ELIGIBLE ORGANIZATIONS.—An organization 
eligible for the grant under subsection (a) is any national 
nonprofit organization that represents, provides technical 
assistance and training to, and has special expertise and 
broad, national-level experience in community antidrug 
coalitions under this subchapter. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00136
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
137 
HR 5925 RFS 
‘‘(c) USE OF GRANT AMOUNT.—The organization 
that receives the grant under subsection (a) shall continue 
a National Community Anti-Drug Coalition Institute to— 
‘‘(1) provide education, training, and technical 
assistance for coalition leaders and community 
teams, with emphasis on the development of coali-
tions serving economically disadvantaged areas; 
‘‘(2) develop and disseminate evaluation tools, 
mechanisms, and measures to better assess and doc-
ument coalition performance measures and out-
comes; and 
‘‘(3) bridge the gap between research and prac-
tice by translating knowledge from research into 
practical information. 
‘‘(d) AUTHORIZATION
OF APPROPRIATIONS.—The 
Director shall, using amounts authorized to be appro-
priated by section 1028, make a grant of $2 million under 
subsection (a), for each of the fiscal years 2019 through 
2023. 
‘‘§ 1027. Definitions 
‘‘In this subchapter: 
‘‘(1) ADMINISTRATOR.—The term ‘Adminis-
trator’ means the Administrator appointed by the 
Director under section 1021(c). 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00137
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
138 
HR 5925 RFS 
‘‘(2) COMMUNITY.—The term ‘community’ shall 
have the meaning provided that term by the Admin-
istrator. 
‘‘(3) ELIGIBLE COALITION.—The term ‘eligible 
coalition’ means a coalition that meets the applicable 
criteria under section 1022(a). 
‘‘(4) GRANT RECIPIENT.—The term ‘grant re-
cipient’ means the recipient of a grant award under 
section 1022. 
‘‘(5) PROGRAM.—The term ‘Program’ means 
the program established under section 1021(a). 
‘‘(6) SUBSTANCE USE AND MISUSE.—The term 
‘substance use and misuse’ means— 
‘‘(A) the illegal use or misuse of drugs, in-
cluding substances for which a listing is in ef-
fect under any of schedules I through V under 
section 202 of the Controlled Substances Act 
(21 U.S.C. 812); 
‘‘(B) the misuse of inhalants or over the 
counter drugs; or 
‘‘(C) the use of alcohol, tobacco, or other 
related product as such use is prohibited by 
State or local law. 
‘‘(7) YOUTH.—The term ‘youth’ shall have the 
meaning provided that term by the Administrator. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00138
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
139 
HR 5925 RFS 
‘‘§ 1028. Drug–free communities reauthorization 
‘‘(a) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to the Office to carry 
out this subchapter $99 million for each of the fiscal years 
2019 through 2023. 
‘‘(b) ADMINISTRATIVE COSTS.—Not more than 8 
percent of the funds appropriated for this subchapter may 
be used by the Office or, in the discretion of the Director, 
an agency delegated to carry out the program under sec-
tion 1021(d) to pay for administrative costs associated 
with carrying out the program.’’. 
(d) TECHNICAL AND CONFORMING AMENDMENT.— 
The table of chapters for subtitle I of title 31, United 
States Code, is amended by adding at the end the fol-
lowing new item: 
‘‘10. Office of National Drug Control ...................................................... 1001’’. 
SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PRO-
GRAM. 
(a) ESTABLISHMENT.— 
(1) IN GENERAL.—There is established in the 
Office a program to be known as the High Intensity 
Drug Trafficking Areas Program (in this section re-
ferred to as the ‘‘Program’’). 
(2) PURPOSE.—The purpose of the Program is 
to reduce drug trafficking and drug production in 
the United States by— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00139
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
158 
HR 5925 RFS 
(IV) evaluating barriers to inte-
grating program data with electronic 
health records; and 
(V) offering recommendations to 
address identified barriers; and 
(ii) to develop standards, and encour-
age the use of such standards, for the col-
lection of data necessary to understand 
and monitor the opioid crisis, including— 
(I) State medical examiner re-
ports on deaths caused by overdoses 
and related statistical data; and 
(II) first responder opioid intoxi-
cation incidents. 
(I) Research initiatives, to be initiated not 
later than 30 days after the issuance of the 
plan, to evaluate the uses and barriers to use 
of and the effects of improving the following 
programs: 
(i) Medication Assisted Treatment. 
(ii) Data collection systems used to 
confirm opioid use by individuals who have 
been arrested or hospitalized. 
(J) A requirement for an Advisory Com-
mittee on Substance Use Disorder Treatment 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00158
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS